Vivet Therapeutics will be at BIO Europe in Berlin on November 6-8th 2017
Vivet Therapeutics will be presenting at Gene Therapy for Rare Disorders Europe on Oct 31-Nov 2, 2017
Vivet Therapeutics will be at
Vivet Therapeutics will be attending the upcoming
Vivet Therapeutics will be at the upcoming European Society of Gene And Cell Therapy (ESGCT) annual meeting in Berlin on Oct. 17-20,…
PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017's
PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product
In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However, as many as 30 million people may suffer from one of the more than 6,000 existing rare diseases.
This section of the website provides information for companies and individuals involved in developing and marketing medicines for human use in the European Union (EU)
A useful resource of Cellular & Gene Therapy Guidance Documents